Menu
SOPHiA GENETICS is excited to be a part of the BioData World Congress 2022 annual meeting, held in-person November 8-10 in Basel, Switzerland.
Throughout the congress, our experts will be pleased to meet you at booth #99 to explore how we can help you access high-quality, real-world multimodal data in real-time.
Join us for our panel discussion on Wednesday 09 November at 12:05pm
"Hope or Hype?: The Importance of Multimodal Data Integration to Advance Precision Medicine"
Our panelists will debate the importance of combining a diversity of data modalities for the longitudinal follow-up of patients from diagnosis to treatment to outcomes, to develop a better understanding of the patient journey and to identify patient subpopulations for precision medicine.
The panel discussion will focus on:
Panelists
David Dellamonica, MBA - Head, Digital and Innovation, Oncology Europe & Canada, AstraZeneca
Michael G. Frank, MBA – Digital Ventures Lead, Memorial Sloan Kettering Cancer Center
Jacques Cadranel, MD, Oncologist, Pneumology Service - Sorbonne Université and AP-HP Hôpital Tenon Paris
Philippe Menu, MD, PhD, MBA – Chief Medical Officer, SOPHiA GENETICS
Moderator
Peter Casasanto, MBA – Chief BioPharma Officer, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
